Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipsen Moves Aggressively On U.S. Strategy, Builds Out Commercial and R&D Infrastructure

This article was originally published in The Pink Sheet Daily

Executive Summary

As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.

Advertisement

Related Content

Ipsen’s U.S. Business Could Be Profitable In 2016, A Year Early
People In The News: Tracking The Latest Industry Personnel Moves
Botox And Beyond: Allergan Lays Out Growth Strategy
In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Ipsen's New Chief Outlines Growth Plans In U.S., Emerging Markets

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel